What one share of Mineralys Therapeutics holds
We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).
Mineralys Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.38 |
|---|---|
| Cash and investments | $1.56 |
| Debt | $0.00 |
| Book value | $6.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$5.77 | — | — | — | −$8.14 |
| 2023 | — | −$1.99 | $0.00 | −$2.24 | — | $5.86 |
| 2024 | — | −$3.66 | $0.00 | −$3.43 | — | $3.84 |
| 2025 | — | −$2.29 | $0.00 | −$2.11 | — | $7.93 |
Common questions about Mineralys Therapeutics
How much does one share of Mineralys Therapeutics earn?
Over the last 12 months, Mineralys Therapeutics lost $4.38 for each share.
Does Mineralys Therapeutics pay a dividend?
Mineralys Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Mineralys Therapeutics’s book value per share?
Mineralys Therapeutics’s book value is $6.24 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Mineralys Therapeutics have?
Each share of Mineralys Therapeutics has $1.56 of cash and investments and $0.00 of debt, as of June 30, 2026.
Has Mineralys Therapeutics bought back shares?
Mineralys Therapeutics’s share count rose about 1209% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.